Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mice deficient in PI3K(p110alpha) displayed accelerated heart failure in response to dilated or hypertrophic cardiomyopathy.
|
17404510 |
2007 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study suggests that targeting the cardiac IGF1R-PI3K(p110alpha) pathway could be a potential therapeutic strategy for the treatment of heart failure.
|
14597618 |
2004 |
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, PI3Kgamma may represent a novel therapeutic target for the treatment of decreased cardiac function in heart failure.
|
12963636 |
2003 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulation of cardiac PI3K/mTOR signaling by HDL could represent a novel therapeutic strategy for heart failure.
|
28904868 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transvenous endomyocardial biopsies were obtained in 52 hypertensive patients with left ventricular hypertrophy: 28 without heart failure and 24 with heart failure. gp130 and gp130-dependent antiapoptotic pathways p42/44 mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) as well as gp130 agonist cardiotrophin-1 were analyzed by reverse transcriptase-polymerase chain reaction and western blot.
|
17885560 |
2007 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rb1 inhibits autophagy through regulation of Rho/ROCK and PI3K/mTOR pathways in a pressure-overload heart failure rat model.
|
29574918 |
2018 |
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the cardioprotective properties of APC in ischemic heart disease and heart failure with a special emphasis on recent discoveries related to the modulatory effect of APC on AMP-activated protein kinase (AMPK), PI3K/AKT, and mTORC1 signaling pathways.
|
30974752 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways.
|
28624424 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
QSKL protects against myocardial apoptosis on heart failure via PI3K/Akt-p53 signaling pathway.
|
29209026 |
2017 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats.
|
30864233 |
2019 |
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR).
|
21631421 |
2011 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulation of cardiac PI3K/mTOR signaling by HDL could represent a novel therapeutic strategy for heart failure.
|
28904868 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats.
|
30864233 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
QSKL protects against myocardial apoptosis on heart failure via PI3K/Akt-p53 signaling pathway.
|
29209026 |
2017 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mice deficient in PI3K(p110alpha) displayed accelerated heart failure in response to dilated or hypertrophic cardiomyopathy.
|
17404510 |
2007 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transvenous endomyocardial biopsies were obtained in 52 hypertensive patients with left ventricular hypertrophy: 28 without heart failure and 24 with heart failure. gp130 and gp130-dependent antiapoptotic pathways p42/44 mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) as well as gp130 agonist cardiotrophin-1 were analyzed by reverse transcriptase-polymerase chain reaction and western blot.
|
17885560 |
2007 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways.
|
28624424 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent investigation of the downstream effector pathways for these growth factors has identified molecules involved in the progression of cardiac hypertrophy and heart failure, including phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR).
|
21631421 |
2011 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study suggests that targeting the cardiac IGF1R-PI3K(p110alpha) pathway could be a potential therapeutic strategy for the treatment of heart failure.
|
14597618 |
2004 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rb1 inhibits autophagy through regulation of Rho/ROCK and PI3K/mTOR pathways in a pressure-overload heart failure rat model.
|
29574918 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, PI3Kgamma may represent a novel therapeutic target for the treatment of decreased cardiac function in heart failure.
|
12963636 |
2003 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ulinastatin induced the activation of the phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine protein kinase (Akt) signaling pathway and downregulated the p38 mitogen‑activated protein kinase (MAPK) and nuclear factor (NF)‑κB pathway in isoproterenol‑induced CHF rats.
|
29115471 |
2018 |
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the cardioprotective properties of APC in ischemic heart disease and heart failure with a special emphasis on recent discoveries related to the modulatory effect of APC on AMP-activated protein kinase (AMPK), PI3K/AKT, and mTORC1 signaling pathways.
|
30974752 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The data from the present study suggest that TRIM59 induces epithelial-to-mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma.
|
29805559 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, these findings highlight a key role for PI3K/mTOR signalling in GLI1 regulation in HH-driven cancers and suggest that combined PI3Kα/mTOR inhibition may be particularly interesting for the development of effective treatment strategies in high-risk medulloblastomas.
|
31492956 |
2019 |